Richard Bungay
Chief Executive Officer at DIUL GROUP
Net worth: 5 349 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Powell | M | 63 |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 9 years |
| Richard John Martin Ross | M | 69 |
Diurnal Ltd.
 Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions. | 19 years |
| Fred Garzoni | M | - |
Imophoron Ltd.
 Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | - |
| Martin James Whitaker | M | 48 |
Diurnal Ltd.
Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions. | 11 years |
| Timothy Haines | M | 67 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.
Macrotarg Ltd.
 Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | - |
| Matthew Stork | M | 55 | 5 years | |
| Francesca Cormack | F | - | - | |
| Stephen Symonds | M | 50 | 2 years | |
| John Porter | M | 53 | - | |
| Marcus Wallenberg | M | 68 | 25 years | |
| Jenny Barnett | M | - |
Monument Therapeutics Ltd.
 Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | 5 years |
| Nick Rodgers | M | 65 | - | |
| John Geoffery Goddard | M | 73 | 9 years | |
| Stuart Gall | M | 62 | - | |
| Peter Strandell | M | - |
Nasdaq Corporate Solutions International Ltd.
 Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | - |
| Debra Leeves | F | 62 | 5 years | |
| Damian Marron | M | 62 |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | - |
| David Bevan | M | - | 3 years | |
| Gabriella Halasz-Clarke | F | - |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | - |
| Matthew Thomas Rafter | M | - |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | - |
| Edward Wynell Thomas | M | - |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | - |
| Harry Destecroix | M | 37 |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | 3 years |
| Pradeep Nathan | M | - | - | |
| Stewart Jones | M | - | - | |
| Julian Gilbert | M | 63 |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | 3 years |
| Jonathan Treherne | M | 63 |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Julie Brown | F | 62 | 14 years | |
| David Brennan | M | 70 | 13 years | |
| Nicholas Walters | M | 66 | 8 years | |
| Ian Leslie Ardill | M | 57 | 2 years | |
| Peter Allen | M | 68 | 5 years | |
| Michael Damien Holton | M | 51 | - | |
| Biresh Roy | M | 62 | 2 years | |
| Samuel Cameron Williams | M | 55 | 7 years | |
| Alan Michael Raymond | M | 71 | 7 years | |
| Mitchell Goldman | M | - | 21 years | |
| Danny T. Lowe | M | - | 7 years | |
| Adrian Otte | M | - | 2 years | |
| Tobias George Sykes | M | 54 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | - |
| Sven Håkan Björklund | M | 68 | 10 years | |
| Elizabeth Ann Roper | M | 50 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 6 years |
| Sarah Holland | F | 61 | 5 years | |
| Carl Firth | M | 51 | 9 years | |
| Tao Deng | M | 68 | 6 years | |
| Martin Toal | M | - |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 6 years |
| Jean-Michel Cossery | M | 65 | - | |
| David Festus Charles Moffat | M | - |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 8 years |
| Deborah Jorn | F | 66 | 1 years | |
| Daryl Thomas | M | - | 5 years | |
| Mark A. Smith | M | 68 | 12 years | |
| Hongming Chen | M | 53 | 3 years | |
| Lilian Birgitta Wikström | M | 63 | 5 years | |
| Karl Härfstrand | M | 66 | 1 years | |
| Francis J. T. Fildes | M | 79 | 3 years | |
| Barry Greene | M | 60 | 2 years | |
| Percy N. Barnevik | M | 83 | 5 years | |
| Judith Ann Hemberger | M | 77 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | - |
| Håkan Lars Mogren | M | 79 | 10 years | |
| Thomas Fulton Wilson McKillop | M | 81 | 6 years | |
| Claes E. Wilhelmsson | M | 85 | 14 years | |
| Angus Russell | M | 68 | 19 years | |
| Michael Cola | M | 64 | 8 years | |
| Irwin Scher | M | 84 | 7 years | |
| Robert A. Conerly | M | 65 | 1 years | |
| Klaus Veitinger | M | 62 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 5 years |
| Göran Albert Ando | M | 75 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | - |
| Nils Anders Haegerstrand | M | 63 | 1 years | |
| Ian James Nicholson | M | 64 |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | 8 years |
| Leon Hooftman | M | - |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | - |
| Alf Gunnar Martin Nicklasson | M | 69 | 8 years | |
| Erna Möller | F | - | 8 years | |
| Jan Lundberg | M | 71 | 11 years | |
| Michael Pragnell | M | 77 | 3 years | |
| Debra White | F | 62 | 13 years | |
| Håkan Söderberg | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 75 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Bungay
- Personal Network
